|Bid||24.75 x 0|
|Ask||25.00 x 0|
|Day's Range||24.50 - 25.15|
|52 Week Range||22.50 - 59.25|
|PE Ratio (TTM)||39.30|
|Earnings Date||May 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.80|
STOCKHOLM, March 13, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX:MOB) announces that the company's Nomination Committee has decided to present the following proposal to the Annual General Meeting 2018. The Nomination Committee consists of the Chairman Gillis Cullin representing Östersjöstiftelsen and the members Fredrik Persson representing Zimbrine Holding BV, Anders Rodebjer representing Wolco Invest and Thomas Eklund, Chairman of the Board of Directors in the Company. The Nomination Committee proposes that Thomas Eklund is elected as Chairman of the Annual General Meeting of shareholders 2018.
STOCKHOLM , Feb. 28, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has entered into an agreement with Randob Labs to divest the brand Balmex® for a total consideration of $4.25 million ( 34.6 million ...
STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDA STOCKHOLM , Feb. 13, 2018 /PRNewswire/ -- PERIOD (FULL YEAR 2017)* Net revenue SEK 439.0 million (334.3) EBITDA SEK 89.4 million (77.9) EBITDA margin 20% ...
STOCKHOLM , Jan. 15, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) have received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest ...
STOCKHOLM , Nov. 30th, 2017 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) is reorganizing its sales and marketing operations to better reflect the company's increased focus on the North American market and ...